Aim: This study aimed to evaluate the association between maternal urinalysis findings, particularly leukocyte esterase, and adverse neonatal outcomes among high-risk cesarean section pregnancies.
Methods: A retrospective cohort study was conducted using medical records from a tertiary referral hospital in East Java, Indonesia, for deliveries between July 2023 and June 2024. Pregnant women with placenta accreta spectrum diagnosed based on clinical presentation and ultrasound findings were included by total sampling. Cases with intrauterine fetal death were excluded. Maternal, obstetric, operative, laboratory, urinalysis, and neonatal data were collected. The primary outcome was adverse neonatal outcome, defined as a 5-minute Apgar score <7. Maternal and obstetric characteristics were compared between outcome groups, and multivariable logistic regression was performed to identify factors related to adverse neonatal outcomes.
Results: Out of 123 pregnant women diagnosed with placenta accreta spectrum through clinical assessment and ultrasound examination, one case of intrauterine fetal death was excluded. Urinalysis data were available for 83 of 122 participants; analyses involving urinary markers were therefore restricted to this subset. Among the 122 analyzed participants, 73 had favorable neonatal outcomes and 49 had adverse neonatal outcomes; within the urinalysis subset (n = 83), 50 had favorable and 33 had adverse outcomes. The in-hospital neonatal mortality rate was 6.0%. The adverse outcome group had lower gestational age, more frequent use of general anesthesia, and greater intraoperative blood loss. Among blood laboratory parameters, blood urea nitrogen was the only marker that differed between groups, with higher levels in the adverse outcome group than in the favorable outcome group (5.35 [4.72–6.35] vs. 4.9 [4.0–6.1], p = 0.042). Urinalysis data were available for 83 subjects. In this subset, leukocyte esterase positivity was more frequent in the adverse outcome group than in the favorable group (60.6% vs. 30.0%, p = 0.006; crude OR 3.59, 95% CI 1.40–9.04). After adjustment for red blood cell positivity and proteinuria, leukocyte esterase positivity continued to show higher odds of adverse neonatal outcome (aOR 3.20, 95% CI 1.20–8.55, p = 0.021). Red blood cell positivity and proteinuria were not independently related to adverse neonatal outcome. Nitrite was excluded from the regression model because only one subject had a positive result.
Conclusion: In this retrospective cohort of pregnancies complicated by placenta accreta spectrum, maternal leukocyte esterase positivity was associated with a low 5-minute Apgar score in the subset with available urinalysis. These findings do not currently support treatment decisions based solely on leukocyte esterase positivity. Prospective studies incorporating standardized urine culture and clinical assessment are required before leukocyte esterase can be recommended as a neonatal risk-stratification tool in PAS.

